Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
Imakiire A, Morimoto H, Suzuki H, Masuda T, Yoden E, Inoue A, Morioka H, Konaka T, Mori A, Shirasaka R, Kato R, Hirato T, Sonoda H, Minami K. Imakiire A, et al. Among authors: minami k. Mol Pharm. 2023 Nov 6;20(11):5901-5909. doi: 10.1021/acs.molpharmaceut.3c00736. Epub 2023 Oct 20. Mol Pharm. 2023. PMID: 37860991 Free PMC article.
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A, Tachibana K, Hirato T, Takahashi K. Sonoda H, et al. Among authors: minami k. Mol Ther. 2018 May 2;26(5):1366-1374. doi: 10.1016/j.ymthe.2018.02.032. Epub 2018 Mar 6. Mol Ther. 2018. PMID: 29606503 Free PMC article.
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
Tani J, Ito Y, Tatemichi S, Yamakami M, Fukui T, Hatano Y, Kakimoto S, Kotani A, Sugimura A, Mihara K, Yamamoto R, Tanaka N, Minami K, Takahashi K, Hirato T. Tani J, et al. Among authors: minami k. PLoS One. 2020 Apr 17;15(4):e0231830. doi: 10.1371/journal.pone.0231830. eCollection 2020. PLoS One. 2020. PMID: 32302352 Free PMC article.
Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Yamamoto R, Yoden E, Tanaka N, Kinoshita M, Imakiire A, Hirato T, Minami K. Yamamoto R, et al. Among authors: minami k. Mol Genet Metab Rep. 2021 Apr 18;27:100758. doi: 10.1016/j.ymgmr.2021.100758. eCollection 2021 Jun. Mol Genet Metab Rep. 2021. PMID: 33981582 Free PMC article.
Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
Giugliani R, Martins AM, Okuyama T, Eto Y, Sakai N, Nakamura K, Morimoto H, Minami K, Yamamoto T, Yamaoka M, Ikeda T, So S, Tanizawa K, Sonoda H, Schmidt M, Sato Y. Giugliani R, et al. Among authors: minami k. Int J Mol Sci. 2021 Oct 10;22(20):10938. doi: 10.3390/ijms222010938. Int J Mol Sci. 2021. PMID: 34681597 Free PMC article.
1,584 results